Embryonic stem (ES) cell lines constitute a special class of cell lines derived from the inner cell masses of preimplantation embryos. They are special owing to their unique capability of self renewal and differentiation and propagation in culture for indefinite periods of time. Unlike cancerous cells, they main tain stable chromosomal content and have potential to diffe rentiate into any of the 200 cell type, under appropriate culture conditions. Embryonic stem cell research has gained a tremendous momentum owing to their promises and hopes in regenerative medicine, stem cell therapy, biopharming, and usefulness as in vitro models for studying embryonic develop ment and differen tiation. ES cell research in farm animals provides strong incentives for precise genetic mani pulation for better health, increased disease resistance, increased milk production and desired composition, increased growth rate with improved carcass composition, enhanced reproductive perfor mance and prolificacy. The potential benefits of using ES cells as donor cells in somatic cell nuclear transfer would boost transgenic animal production. However, with all the promises and hopes, need for more rigorous research and evidence-based therapy is the need of the time, before we could successfully embark on exploitation of ES cells in regenerative medicine. In the current review, establishment, charac terization, applications and future challenges of farm animal ES cells are discussed in detail with a special focus on bubaline ES cell lines.
INTRODUCTION
Almost at a time, three decades from now, a breakthrough was achieved when murine embryonic stem cells were isolated from the inner cell mass of developing blastocysts and grown in vitro under usual laboratory conditions. 10, 35 Their two properties left the scientific world in bewilderment: (i) capability to be propagated indefinitely in culture and (ii) ability to contribute to all cell lineages, including germ line, when incorporated into chimeras with intact mouse embryos. 2, 41 Providing a simple model system to study the basic processes of early embryonic development and cellular differentiation, it promised for cell-based therapies for humans if and only if human embryonic stem cell lines could be developed. This would provide a radical new approach to the treatment of variety of disease in which organ damage exceeds the body's natural repair capability. A genuine belief that stem cell research will deliver a revolution in terms of how we treat cardiovascular disease, neurodegenerative disease, cancer, diabetes, and the like, propelled the research at such a pace that the feat was accomplished within a decade with the publication of two papers describing the growth in vitro of human embryonic stem cells derived either from the inner cell mass (ICM) of the early blastocyst or the primitive gonadal regions of early aborted fetuses. 54, 62 In the mean time, extensive studies carried out worldwide in stem cell research demonstrated the usefulness of these cells for the introduction of both dominant and recessive mutations into the murine germ line. 67 These studies together with the ability for production of unlimited number of cells, while still retaining the developmental potential, provided a strong incentive for the isolation of domestic animal embryonic stem (ES) cells. The speculations that the development of ES cell lines of domestic livestock, such as cattle, buffalo, sheep and goat, would greatly facilitate precise genetic manipulation for better health, increased disease resistance, increased milk production and desired composition, increased growth rate with improved carcass composition, enhanced reproductive performance and prolificacy, demonstrated their usefulness at par with those of human ES cell lines. The potential to produce transgenic animals using ES cells and their use as models for human diseases, cell transplantation therapies, and studies of lineage commitment and development 66 further added to the zeal. In addition, the exploitation of these cells for biopharming, the production of recombinant proteins for the treatment and prevention of human and animal diseases, 32, 34 and development of genetically modified animals to serve as bioreactors with capability of secreting commercially important mammalian proteins in their fluids 36 added to their further usefulness and thereby scientific research. But before these potentials could be realized, a large number of problems had to be overcome. The first and foremost was to develop the means of pro ducing a sufficient number of healthy embryos under laboratory conditions followed by development of efficient methodologies to isolate the ES cells from small number of such elite embryos. The second difficulty was to obtain and maintain the ES cell lines which would reproductively contribute to the germ line. This was further compounded by the differences between mouse and farm animals in reproductive behavior and generation time. Because of shorter generation time in mice, it is possible to produce chimeras that can be bred to obtain mice which are heterozygous and then homozygous for the introduced mutation. Since, domestic animals have a longer generation time and it is desirable to maintain the elite genetic background of such ES cells, techniques which will produce 100% ES cell-derived animals had to be developed. Despite all these challenges, the ES cell research in domestic animals proceeded at a pace, next only to human ES cell research and within a span of time we had ES cell lines or ES cell-like lines for bovine, 3, 7, 11, 25, 37, 53, 57, 65 ovine, caprine and equine 27, 43, 53 as well as porcine. 17, 33 Our lab was the first to develop ES cell-like cells from in vitro produced buffalo embryos that survived up to eight passages. 64 From thereon, the continuous research in our lab resulted to development of fully characterized ES cell lines of bubaline species, derived from the inner cell masses of in vitro fertilized, parthenogenetic as well as handmade cloned (SCNT) embryos. 39, 71 We have been successful in maintaining the ES cell line derived from IVF-embryos beyond 100 passages. Furthermore, we have been able to optimize their culture conditions, decipher their signalling pathways, analyze the expression pattern of pluripotency markers, and study their differentiation strategies into a desires cell type. 39, 55, 71 Our current research focuses on use of these cells for transgenic animal production either through our in-house developed handmade cloning (HMC) technique or through their directed differentiation into germ line cells (Shah et al-unpublished data). Using HMC technique, we have already been able to produce world's first buffalo calf (Garima II) using ES cell as the donor cell. The calf is in a sound physiological and reproductive health and has recently given birth to a normal calf (Mahima) through artificial insemination (Fig. 1) .
One of the challenging problems facing stem cell research is the accumulation of mutations while the cells are in culture and the instability of XX murine ES cell lines, and the cell lines of other species also, as seen by some researchers. 51 
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ESTABLISHMENT OF BUFFALO CELL LINES
Initial research into the isolation of domestic animal ES cells in our and other laboratories attempted to repeat the work carried out in mice by isolating cell lines directly from cultured preimplantation embryos. ICM is removed from the blastocysts, either mechanically, enzymatically or by applying antibodies (immunosurgery) and cultured on appro priate feeders to obtain a stem cell line. 59 The feeders most often consist of homologous feeder cells treated with mitomycin C. In our laboratory, we isolate ICMs of hatched blastocysts, derived either from IVF, handmade cloning or parthenogenesis, by mecha nical cutting with the help of Microblades TM under a zoom stereomicroscope (Olympus, SZ40, Japan). The iso lated ICMs are then seeded individually and sepa rately on the feeder layers (buffalo fetal fibroblasts treated with Mitomycin C (10 µg/ml for 3 hours), and cultured in embry onic stem cell media. The media which has been opti mized for maximum stem cell growth and maintenance of pluri potency 39, 55 is composed of KODMEM and 15% knock out serum replacer (KSR) supplemented with 2 mM L-glutamine, 5 ng/ml bFGF-2. 1000 U/ml recombinant murine leukemia inhibitory factor (rmLIF), 1X nonessential amino acids and 50 mg/ml gentamicin sulfate and incubated at 37 to 38ºC in 5% CO 2 . The culture medium is changed on alternate days, and further colonization of the cells is observed routinely under an inverted microscope. The primary colonies obtained 8 to 10 days after seeding of ICMs are disaggregated with the aid of microblade under a zoom stereomicroscope. Aggregates of cells are individually reseeded onto a new feeder layer. The colonies exhibiting typical morphological features of ES cell-like cells are subcultured using mechanical dissociation until the cells remained in an undifferentiated state or when colony formation stops (Fig. 2) . The dissociated colonies are subcultured on to new feeder layers and further passaged after every 8 days onto the new feeders and so on. Some of the colonies are randomly choosen for characterization for embryonic stem cell markers, karyotyping and embryoid body formation. After confirming their stemness, the colonies are cryopreserved at different passages so as to maintain the stock while the remaining colonies are propagated for further studies. Embryonic stem cells, in general, can also be grown under feeder-free conditions using dishes coated with animal-based ingredients with the addition of MEF-cell (mouse embryonic feeder) conditioned medium. 52 Such systems are not optimal for the derivation and growth of clinical grade human ESC lines since, they bear a risk of cross transfer of infectious agents. There are also reports of high differentiation rates of these cell lines and genomic instability after prolonged in vitro growth 4 revealing the limitations of applied feeders or feeder free systems for growth of undifferentiated human ESC lines. When plated on feeder layers in appropriate culture medium, the ICM clumps are allowed to adapt to the new culture conditions and get attached to the feeder cells and start growing. It has been observed that ICM clumps with 
CHARACTERIZATION OF ES CELL LINE
Given the historical introduction of the term 'ES cell' and the properties of mouse ES cells, the essential charac teristics of primate ES cells should include (i) derivation from the preimplantation or peri-implantation embryo, (ii) prolonged undifferentiated proliferation and (iii) stable developmental potential to form derivatives of all three embryonic germ layers even after prolonged culture. 63 For ethical and practical reasons, in many primate species, including humans, the ability of ES cells to contribute to the germ line in chimeras is not a testable property and hence, is not considered as a pre requisite for ES cell characterization. The mouse ES cells provides a benchmark for definition of the generic features that any ES cell might be expected to possess, and other properties which may be peculiar to bona fide pluripotent cells isolated from different species or different tissues, or representative of a different stage of embryonic development. Its key features include: derivation from a pluripotent cell population; stably diploid and karyotypically normal in vitro; ability to be propagated indefinitely in the primitive embryonic state; capability of spontaneous differentiation into multiple cell types representative of all three embryonic germ layers, both in teratomas after grafting or in vitro under appropriate conditions; potential to give rise to any cell type in the body, including germ cells, when allowed to colonise a host blastocyst. The criteria for pluripotency usually include derivation of the stem cell line from a single cloned cell which eliminates the possibility that several distinct committed multipotential cell types are present in the culture that together account for the variety of differentiated derivatives produced. 46 To ensure that the line so established is a true stem cell line various other attributes like morphological resemblance, pluripotency related marker expression, growth requirements and self renewal capability are also taken into account. To characterize our ES cell lines, as true ES cell lines, we adhere to following established criteria in our laboratory:
Morphology of ES Cell Colonies
Mouse and human ES cell colonies have a characteristic morphology. They usually proliferate in tight roundshaped colonies with smooth edges. 10 The morphology of ES cells has two important traits-they have quite small amount of cytoplasm and they exhibit faster proliferation rate in a given population of cells. However, for many animals, such as cow, sheep, pig, horse, hamster, mink, rabbit, primates, embryo derived ES cells are found to propagate as flattened colonies, almost as a monolayer with individually distinct cells that have been described as epithelial-like or epitheloid 12 whereas in case of buffalo the primary colonies have been observed to be dome shaped with abundant lipid-like vacuoles 64 ( Fig. 3) .
Cytogenetic Analysis
The karyotyping of ES cells has recently received much attention in most laboratories; this has been studied by G-banding, with most ES cells exhibiting a normal compliment of chromosomes. Karyotyping is generally performed at different passages in order to know the genetic stability of ES cells during culture (Fig. 3) .
Expression of Various Surface Markers
Alkaline Phosphatase, Stage Specific Embryonic Antigens, Tumor Rejection Antigens
Alkaline phosphatase (ALP) enzyme is secreted by almost all the cells but its intensity is found to be higher in undifferentiated cells. ALPs located at the cell surface are linked to the cell membrane via a phosphati dylinositol-glycan linkage. ES cells are known to express a high specific activity of ALP, which declines during progressive differentiation resulting in low ALP activities in differentiated cells. Mouse ES cells display ALP activity 48, 51 as do most tested human ES cell lines 15, 58 but the signal for this pluripotent cell marker seems to 
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be variable in bovine ES cell-like cells. 16 ALP has been used as a marker for porcine ES cells, sheep ES cell lines, canine stem cell-like cells 60 and buffalo ES cell-like cells 6 and by many groups in bovine as an indicator for ES cells 18 (Fig. 3) .
Stage Specific Embryonic Antigens
The accessibility of molecules on the surface of cells make them exceptionally convenient markers for characterizing cell types, often recognized as antigen by speci fic antibodies. Cell surface antigens provide an invaluable tool for analyzing and sorting cells that have particular characteristics within specific contexts.
A number of surface markers have been used for the charac terization of ES cells ( (Fig. 4) . The other two most widely studied ES cell pluripotency surface markers are SSEA-3 and SSEA-4. They are related to globoseries cell surface glycolipids that were first used to delineate embryological changes in the developing mouse embryo. 56 These markers were originally identi fied on human EC (embryonic carcinoma) or ES cells and from primate ES cells like rhesus monkey.
61
In mouse ES cells, SSEA-3 and SSEA-4 are expressed in 2 to 8-cell and morula stages of preimplantation embryos and are also found on unfertilized oocytes; however, there is a loss of expression in the ICM of mouse embryos. In contrast, in human embryos, there is no expression of SSEA-3 or SSEA-4 at 2 to 8-cell or morula stages; however, these are expressed on the ICM of human blastocysts and on isolated human ES cells. 21 Whereas SSEA-3 and SSEA-4 are expressed in sheep and bovine, the buffalo ES cell like cells also showed the expression of SSEA-3 and SSEA-4. 28 However, our group has observed lack of expression of SSEA-3 in buffalo ES cells but SSEA4 was positively expressed in all our cell lines (Fig. 4) .
Tumor Rejection Antigens
Another class of surface markers for pluripotent cells is that of tumor rejection antigens (TRA) series. TRA-1-60 reacts with a sialidase-sensitive epitope while TRA-1-81 reacts with an unknown epitope of the same molecule. ES cells from primates like rhesus monkey have shown to express TRA-1-60 and TRA-1-81. 69 The expression of TRA-1-60 and TRA-1-81 has also been reported in buffalo ES cell-like cells. 28, 55 We have also detected their expression in our ES cell line (Fig. 4) .
Transcription Factors as Markers of Pluripotency
A number of transcription factors play critical role in main taining stem cell self-renewal and their expression is being used to characterize ES cells in different species. Among them Oct4, Sox2, Nanog, Foxd3 and Rex1 are thought to be central to the transcriptional regulatory hierarchy that specifies ES cell identity because of their unique expression patterns and essential role during early development.
42
Oct4 is a transcription factor belonging to the class V of POU family factors and is expressed by all pluripotent cells during embryogenesis. Oct4 has also been established as a marker for human pluripotent ES cells. However, in bovine cells, the usefulness of Oct4 has been questioned by the identification of a bovine Oct4 pseudogene. The expression of Oct4 in undifferentiated pluripotent cells has also been shown in various other species like canine, goat and buffalo. 64 We have detected the consistent presence of Oct4 in our ES cell lines (Fig. 4) .
Nanog is a homeobox-containing transcription factor with an essential function in maintaining the pluri potency of the ICM cells. Furthermore, over expression of Nanog is capable of maintaining the pluripotency and self-renewal characteristics of ES cells under the conditions where normally the cells would be exposed to differentiation-inducing culture conditions. 5 Nanog seems to be one out of the several factors that are expressed in pluripotent cells and are down regulated at the onset of differentiation. Nanog mRNA was detected in the ICM but not in the TE of expanded goat blastocysts. 20 A pattern that follows the expression observed in mice. We have observed the expression of this transcription factor throughout our established cell lines (Fig. 4) . We have likewise detected the expression of other transcription factors like Rex1, c-Myc, Sox2 in our established ES cell cultures both via immunocytochemistry of ES cell colonies as well as by
RT-PCR (Figs 4 and 5).
Differentiation
The most definitive test of pluripotency is the formation of chimeras in mice in which ES cells are injected into 
CLONING LIVESTOCK-THE POTENTIAL OF ES CELLS
The first successful cloning of adult mammals 68 helped to overturn previous conceptions regarding the restricted developmental plasticity of somatic cells, and is raising exciting prospects for human regenerative medicine. 8 In addition, somatic cloning, coupled with genetic modification, will better enable production of human therapeutics as well as xenograft tissues and organs from livestock. 70 Opportunities for animal cloning and trans genesis in agriculture are more challenging than bio medical applications because they require greater biological efficiency and at reduced cost to be economically viable. Another potentially difficult issue concerns with the consumer acceptance of the food products, resulting from this technology. For the production of transgenic livestock, embryonic stem cells might be beneficial than somatic cells, because they are more amenable to precise genetic modifications and result in higher cloning efficiencies than somatic cells in the mouse. Even with the most streamlined techniques, only 9% of zona-free somatic-cell cloned bovine embryos transferred to recipients result in viable calves at weaning. 44 This level of cloning efficiency is considerably lower than the 40% of bovine IVF embryos that typically develop into healthy calves. 30 The continuous loss of clones throughout pregnancy and high mortality during the perinatal period raise serious animal welfare concerns, especially for cattle, in which at least 60% of initiated pregnancies suffer severe placental abnormalities. 23 These losses have mostly been attributed to faulty epigenetic reprogramming of the donor cell genome, resulting in major dysregulation of gene expression, 50 particularly in the placenta 24 with long-lasting effects into adulthood in some surviving somatic cell clones. 45 Evidence from mouse cloning suggests that choosing particular donor cell types for nuclear transfer (NT) could overcome many of these cloningspecific problems. Although no wellcontrolled studies have directly compared cell types within one cellular lineage of the same genotype, it is nonetheless clear that the degree of donor cell differentiation affects cloning efficiency. A higher proportion of transferred cloned embryos recons tructed from less-differentiated embryonic blasto meres or (murine) ES cells (pluripotent cells derived from embryonic blastomeres) result in viable offspring when compared with somatic cell clones. Cloning efficiencies with blastomere donors are approximately one order of magnitude higher than with somatic cells (36% vs 0.6% in mice 31 and 28% vs 5% in cattle). 22 Although abnormal phenotypes are still observed with blastomere cloning, their incidence and severity are greatly reduced. Cloning efficiency with F1 mouse ES cells is similarly remarkable, with 10 to 20% of transferred embryos reaching adulthood, compared with only 1 to 3% in the case of commonly used somatic donor cells (fibroblasts and cumulus cells) and less than 0.03% for terminally differentiated cell types (B or T lymphocytes). 26 The candidate gene expression profiling
shows that all ES cell-derived blastocysts faithfully express key embryonic genes, such as Oct4 and related genes, present in the pluripotent cells of the early embryo, whereas 38% of cumulus-cloned blastocysts failed to reactivate these genes. 1 Although such detailed molecular analyses have not yet been performed with blastomere derived cloned embryos, it is likely that blastomeres also retain an epigenotype compatible with early embryonic development without the need for extensive reprogramming. We have been successful in cloning buffalo calves from a wide variety of cells ranging from buffalo fetal ear fibroblasts (Garima), adult ear fibroblasts (Purnima and Shresth), seminal epithelial cells (Swarn) and ES cell (Garima II).
APPLICATIONS OF STEM CELLS IN REGENERATIVE MEDICINE
Regenerative medicine is regarded as the future healthcare for it holds the potential for extending the reach of treatment modalities for individuals across diseases and lifespan. This aspect of medicine is believed to provide innovative solutions to complications ranging from congenital diseases and trauma to degenerative conditions. Stem cells, whether adult, embryonic or induced pluripotent, provide multipurpose and excellent research and clinical tools to understand and model diseases, develop and screen candidate drugs, and deliver cell-replacement therapies to support regenerative medicine. Stem cells are currently used to test/screen drugs or as the study material to identify molecules or genes implicated in regeneration. Reprogramming technology to produce iPSCs offers the potential to treat diseases like Alzheimer's, Parkinson's, cardiovascular, diabetes, and amyotrophic lateral sclerosis. In theory, easily-accessible cell types (such as skin fibroblasts) could be biopsied from a patient and reprogrammed, effectively recapitulating the patient's disease in a cul ture dish. Such cells could then serve as the basis for autologous cell replacement therapy. Since, cells originate within the patient, immune rejection of the differentiated derivatives would be minimized. As a result, the need for immunosuppressive drugs to accompany the cell transplant would be lessened and perhaps eliminated altogether. In addition, the reprogrammed cells could be directed to produce the cell types that are compromised or destroyed by the disease in question. 9 Stem cell therapies are trialed in a number of medical complications to restore the function of a damaged tissue or organ like trans plantation of patient's own stem cells (e.g. from bone marrow) to restore the cardiac damage and regenerate cardiac myocytes. The results have been mixed, though recent trials have shown a small but significant improve ment in heart function. 47 In another example, 40 The applications of stem cell therapy, both in native state as well as genetically modified, is ever increasing encompassing almost every complications and it is beyond my scope to review all of them here. So, much are the advances exciting that a dilemma exists as to whether continue research to learn more about stem cells and their properties is required or to go straight to the patients with the miraculous cells in hand.
CHALLENGES IN STEM CELL RESEARCH: LOOKING AHEAD TO 2014
The stem cell research field has reached a critical juncture in 2013, where we find ourselves buoyed by building momentum for both transformative basic science discoveries and clinical transformation of the stem cells.
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The overall prospect of novel stem cell based therapies becoming a reality comes with its own challenges apart from the technical ones, like stem cell tourism, formal physician training in stem cells, regulatory compliance balanced with innovation, savvy educational outreach 29 and the risk of unproven therapies. Stem cell tourism is a small but growing part of the thriving global medical tourism marketplace where a patient travels to other country for getting stem cell therapy which is per se banned in his own country. Though much stem cell research remains at the experimental stage, with clinical trials still uncommon, yet there are over 700 clinics estimated to be operating in mostly developing countries like Costa Rica, Argentina, China, India and Russia, that are enticing many patients, mostly from industrialized countries. These stem cell tourists driven by desperation and hope, in turn continue to fuel the growth of such tourism. This 'magic cure by stem cells' approach must be condemned under all circumstances. If there is no chance of improvement in the patient's condition, the 'therapy' is both unethical and scientifically and clinically unacceptable. The risks for adverse effects may be high; and it will not contribute to the development of clinicallyestablished stem cell therapies, thus cutting the axe at its own feet. Prevention of stem cell tourism, together with a formal training of the stem cell based health practitioners curb on stem cell myths and misinformation propagated by TV shows, magazines, movies and other pop-culture avenues which remains the major challenges of the day. The stem cell community needs to take action in the coming time to use social media to promote evidence based stem cell medicine so as to take care of the hope and make the distinction clear between the 'hope or illusion' and the 'informed hope'. According to Knoepfler 
CONCLUSION
The potential of stem cell research for treatment has received praises from all over, from genuine idealism and optimism toward the practical ability of modern medicine. This however, warrants the need for more rigorous research and therapy based on evidence not on hope.
Human beings would be always attracted toward the sciences which offer the hope of escaping diseases, death and decay, and within this backdrop stem cell science was and is seen with much hope and hype. It is this confluence of hope and hype that created demand for stem cell treatments that the science of clinical applications was not yet ready to accommodate. This is an effect which the stem cell advocates themselves contributed by rousing the public excitement, to the creation of offshore markets which are a havoc of the time. Thus, the need of the hour is to more vigorously criticize the charlatans who under the disguise of modern treatment either offer a placebo to the patients or do the harm in the hope of cure, depriving the people both economically as well as medically. More extensive research must be performed using stem cells from animals which are presumed to be evolutionary more closer to humans than mice and multiple animal models across species must be raised for a particular diseases for which stem cell therapy or intervention is sought, before the cure could be offered to the ailing humanity.
